SPOTLIGHT: Akela faces delay

Akela Pharma says it's facing a delay developing Fentanyl Taifun for breakthrough cancer pain after the FDA rejected toxicology studies saying that deviations in Good Laboratory Practice had invalidated the results. Akela says that the decision won't delay its submission for regulatory approval by more than six months. Fentanyl Taifun is a formulation of Fentanyl delivered by Akela's Taifun inhaler technology. Release

Suggested Articles

Across its 15-year history, Omega Funds has a hand in a clutch of high-profile biotechs such as Editas Medicine and Juno Therapeutics.

After Novartis’ near $10 billion buyout of The Medicines Company, many thought cardiovascular therapies were hot again.

Mutations in RIPK1 can cause uncontrolled cell death and inflammation, researchers discovered by studying families with an autoimmune disorder.